Speaker: Giovanni Mancardi, Professor of Neurology, University of Genova
What inspired you to be part of the Scientific Programme at ECTRIMS 2022?
Giovanni Mancardi: I will be part of the ECTRIMS European Academy of Neurology meeting. So it would be a joint meeting between the two associations and they decided to have a meeting on the bone marrow transplantation
What key insights do you plan to share during your session?
Giovanni Mancardi: So my presentation will be focused on the clinical efficiency of our XXX (tolerance) of hematopoietic stem cell transplantation in multiple sclerosis. Now we know that, we have almost 10-15% of MS cases that have aggressive clinical course. And bone marrow transplantation can be a possible procedure for this type of patients. I will underline that all the phase 1 and phase 2 studies that have been done on bone marrow transplantation in multiple sclerosis, they demonstrate that at least 7% of relapse remitting multiple sclerosis after five years from the procedure, they do not have any kind of relapse or MRI activity. And also, there is an important, relevant clinical effect on disability worsening. That is, after five years, almost 80-85% do not have a progression of disability. And after 10 years, almost 60-70% of cases there are stable, and they do not worsen as far as the disability is concerned. We have also a definitely interesting point that almost 50% of cases they can improve the neurological situation after five years.
